1. It's like a new biotech company founded by the same 'dream team' that developed Merck's blockbuster cancer drug, Keytruda.

2. Consider it a 'full-stack' biotech company, led by the scientific minds behind blockbuster drugs like Keytruda, that builds new cancer therapies from the ground up using advanced internal technology.

Major Products of Eikon Therapeutics (EIKN):

• EIK1001: A TLR 7/8 dual-agonist in Phase 2/3 trials for advanced melanoma and non-small cell lung cancer.
• EIK1003: A selective PARP1 inhibitor in Phase 1/2 trials for ovarian, breast, prostate, and pancreatic cancers.
• EIK1004: A selective, brain-penetrant PARP1 inhibitor in Phase 1/2 trials for ovarian, breast, prostate, pancreatic cancers, and brain malignancies.
• EIK1005: A Werner (WRN) helicase inhibitor in Phase 1/2 trials for advanced solid tumors, particularly MSI-high tumors.

Eikon Therapeutics (EIKN) is a late-stage clinical biopharmaceutical company focused on the development of novel drug candidates, primarily in oncology. As such, the company is currently engaged in research, development, and conducting clinical trials for its product candidates (e.g., EIK1001, EIK1003, EIK1004, EIK1005).

At this stage of its lifecycle, Eikon Therapeutics does not have commercialized products on the market. Consequently, it does not have major customers that purchase its products or services to generate revenue in the traditional sense. Its primary activities involve advancing its drug pipeline through clinical development.

Merck & Co., Inc. (MRK)

Roger M. Perlmutter, M.D., Ph.D., Chairman, President, and Chief Executive Officer

Dr. Perlmutter was appointed CEO of Eikon Therapeutics in May 2021. He previously served as Executive Vice President of Merck & Co. and President of Merck Research Laboratories, where he oversaw the discovery and development of numerous medicines, including KEYTRUDA™. Before rejoining Merck, he spent 12 years as Executive Vice President and head of R&D at Amgen. Earlier in his career, he held academic positions as a professor and Chairman of the Department of Immunology at the University of Washington and was an investigator of the Howard Hughes Medical Institute. Eikon Therapeutics launched with $148 million in venture fundraising, and Dr. Perlmutter's current company is notably backed by venture capital funds.

Alfred Bowie, Jr., Ph.D., Chief Financial Officer

Dr. Bowie was named Eikon Therapeutics' Chief Financial Officer in June 2021. Prior to joining Eikon, he oversaw corporate and business development, strategic planning, and sales operations at Veracyte, where he also led multiple acquisitions. He previously held the role of Senior Director, Corporate Development & Strategy at Foundation Medicine, a wholly-owned subsidiary of Roche, focusing on strategic planning, corporate development, and competitive intelligence. Dr. Bowie's background also includes corporate and business development positions at Tecan Group and Danaher Corporation, and he began his career in management consulting at The Boston Consulting Group.

Roy Baynes, M.D., Ph.D., Executive Vice President and Chief Medical Officer

Dr. Baynes joined Eikon Therapeutics as Executive Vice President and Chief Medical Officer in July 2022. His prior experience includes serving as Chief Medical Officer and head of clinical development at Merck, where he led the development strategy for many important medicines, including Keytruda®. Before Merck, Dr. Baynes held clinical development leadership roles in oncology, respiratory, and inflammation at Gilead Sciences, and in hematology/oncology at Amgen. He also held academic positions in hematology and oncology, including leading the bone marrow transplantation service at the Karmanos Cancer Institute at Wayne State University.

Michael Klobuchar, Chief Operating Officer

Mr. Klobuchar joined Eikon Therapeutics as Chief Operating Officer. He previously spent 26 years at Merck, where he held various positions, including chief strategy officer (since 2021) and, prior to that, CFO and head of portfolio and alliance management at Merck Research Laboratories.

Russ Berman, Chief Technology Officer

Mr. Berman serves as Eikon Therapeutics' Chief Technology Officer.

Clinical Development and Regulatory Approval Risk: Eikon Therapeutics' success is fundamentally dependent on the successful development and regulatory approval of its product candidates. The company has several candidates in various phases of clinical trials, most notably EIK1001, which is in a global Phase 2/3 registrational trial. The failure of any of these trials to demonstrate efficacy and safety, or the inability to obtain necessary regulatory approvals from health authorities, would severely impact the company's business and future prospects.

Commercialization and Market Acceptance Risk: Even if Eikon Therapeutics' product candidates, such as EIK1001, receive regulatory approval, there is a significant risk that they may not achieve market acceptance or commercial success. Factors such as competition from existing or new therapies, pricing pressures, manufacturing and supply chain challenges, and the willingness of physicians and patients to adopt the new medicines could hinder their ability to generate substantial revenue.

Eikon Therapeutics (EIKN) is developing several innovative medicines targeting significant unmet medical needs across various oncology indications. The addressable markets for their main product candidates are as follows:

• EIK1001 for Advanced Melanoma: The global advanced melanoma market was valued at approximately USD 4.3 billion in 2024 and is projected to reach USD 11.0 billion by 2035 across the top 7 markets (U.S., EU4, UK, and Japan). Other estimates place the global melanoma treatment market at USD 6.8 billion in 2022, projected to reach USD 12.1 billion by 2028. The global advanced melanoma market size was estimated at $3.77 billion in 2024 and is expected to grow to $5.9 billion in 2029.
• EIK1001 for Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer market was estimated at USD 20.2 billion in 2024 and is expected to grow to USD 53.9 billion in 2034. The global non-small cell lung cancer market size was valued at USD 15.3 billion in 2021 and is projected to reach USD 36.9 billion by 2031. For metastatic non-small cell lung cancer, specifically, the market size was USD 18.50 billion in 2025 and is predicted to increase to approximately USD 50.30 billion by 2035.
• EIK1003 and EIK1004 (PARP1 inhibitors) for Ovarian, Breast, Prostate, and Pancreatic Cancers, and Brain Metastases/Primary Brain Malignancies:
  • Ovarian Cancer: The global ovarian cancer market size was valued at USD 1.35 billion in 2024 and is anticipated to reach USD 31.64 billion by 2033. Another report estimated the global ovarian cancer market size at USD 3.5 billion in 2023, with a projected reach of approximately USD 6.5 billion by 2032. The global ovarian cancer drugs market was estimated at USD 3.84 billion in 2024 and is expected to reach around USD 7.34 billion by 2034, with PARP inhibitors contributing significantly to the market share.
  • Breast Cancer: The global breast cancer market size was estimated at USD 26.23 billion in 2025 and is predicted to increase to approximately USD 40.11 billion by 2035. Another source states the global breast cancer market size was USD 33521.5 million in 2024 and is expected to boost sales to USD 64497.04 million by 2031.
  • Prostate Cancer: The global prostate cancer market size is calculated at USD 12.88 billion in 2025 and is predicted to increase to approximately USD 28.83 billion by 2035. The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market size was valued at USD 21.04 billion in 2025 and is projected to grow to USD 91.85 billion by 2034.
  • Pancreatic Cancer: The global pancreatic cancer market size is expected to reach around USD 10.25 billion by 2034 from USD 3.25 billion in 2025. The global pancreatic cancer market, valued at approximately USD 2,125.57 million in 2023, is projected to reach USD 7,541.09 million by 2033.
  • Brain Metastases: The global brain metastasis therapeutics market size is poised to grow from USD 2,665 million in 2024 to USD 5,589.2 million by 2032. Another estimate projects the market to reach US$ 6.69 billion by 2031.
  • Primary Brain Malignancies: The global brain cancer market is estimated to be valued at USD 4,761.4 million in 2026 and is expected to reach USD 6,586.6 million by 2033. The global brain tumor diagnosis and therapeutics market size was estimated at USD 3.28 billion in 2024 and is projected to reach USD 4.94 billion by 2030.
• EIK1005 (WRN helicase inhibitor) for Advanced Solid Tumors (MSI-high): The global MSI-H/dMMR (microsatellite instability-high/deficient mismatch repair) market, which EIK1005 targets, is expected to be worth around US$ 93.4 billion by 2034, from US$ 8.9 billion in 2024. The MSI-H and dMMR market size is expected to grow from $6.15 billion in 2024 to $17.26 billion in 2029. The global solid tumor cancer treatment market size was accounted for at USD 5.37 billion in 2024 and is expected to reach around USD 8.76 billion by 2034.

Eikon Therapeutics (EIKN), a late-stage clinical biopharmaceutical company, is currently pre-revenue, with future growth anticipated from the successful clinical development and potential commercialization of its pipeline assets. The primary drivers of future revenue growth over the next 2-3 years are centered around the progression and potential market entry of its lead oncology product candidates.

Here are 3-5 expected drivers of future revenue growth for Eikon Therapeutics:

1. Regulatory Approval and Commercialization of EIK1001 for Advanced Melanoma: Eikon's most advanced product candidate, EIK1001, a toll-like receptor (TLR) 7/8 dual-agonist, is in a global Phase 2/3 registrational trial in combination with pembrolizumab for advanced melanoma. The first interim analysis from this study is anticipated in the second half of 2026. Successful completion of this trial, followed by regulatory approval and market launch, would represent the company's initial significant source of product revenue.
2. Advancement Towards Regulatory Approval and Commercialization of EIK1001 in Non-Small Cell Lung Cancer (NSCLC): EIK1001 is also being evaluated in a Phase 2 trial and a Phase 2/3 registrational trial for non-small cell lung cancer (NSCLC) in combination with pembrolizumab and chemotherapy. Data from the Phase 2 trial is expected to be presented in the fourth quarter of 2026, with the first patient in the Phase 2/3 registrational trial anticipated to be dosed in the second half of 2026. Positive clinical outcomes and progression towards regulatory submission would be critical drivers for future revenue generation.
3. Successful Clinical Development and Potential Partnerships for PARP1 Inhibitors (EIK1003 and EIK1004): Eikon is conducting Phase 1/2 trials for its selective PARP1 inhibitors, EIK1003 and EIK1004, across various cancers including ovarian, breast, prostate, and pancreatic cancers, with EIK1004 specifically designed as a CNS-penetrant candidate for brain malignancies. Positive data from these early-stage trials could lead to significant milestone payments from future partnerships or attract further investment, paving the way for later-stage development and eventual commercialization.
4. Successful Clinical Development and Potential Partnerships for WRN Helicase Inhibitor (EIK1005): The company has initiated a Phase 1/2 trial for EIK1005, its internally discovered Werner (WRN) helicase inhibitor, for patients with advanced solid tumors, particularly those with microsatellite instability-high (MSI-high) tumors. Positive clinical data from this program could validate Eikon's proprietary technology platform and potentially lead to out-licensing agreements, collaborations, or direct commercialization efforts in the future.

Share Issuance

• Eikon Therapeutics secured approximately $381 million through its Initial Public Offering (IPO) in February 2026, selling over 21 million shares at $18 apiece.
• The underwriters of the IPO were granted a 30-day option to purchase up to an additional 3.1 million shares, potentially increasing total proceeds to approximately $438 million if fully exercised.

Inbound Investments

• Eikon Therapeutics has raised over $1.1 billion in total private funding since its founding in 2019.
• The company closed a $350.7 million Series D financing round in February 2025, which included participation from existing and new investors such as Lux Capital, Foresite Capital, The Column Group, T. Rowe Price Associates, and UC Investments.
• Previous significant private funding rounds include a $106 million Series C in June 2023 and a $518 million Series B in January 2022, led by T. Rowe Price, CPP Investments, and EcoR1 Capital.

Outbound Investments

• In June 2023, Eikon Therapeutics acquired global rights to develop and commercialize clinical-stage Toll-like receptor 7 and 8 (TLR7/8) agonist immunomodulators from Seven and Eight Biotherapeutics Corp.
• Also in June 2023, the company licensed a portfolio of PARP1-selective inhibitors from Impact Therapeutics.
• Eikon further expanded its pipeline in June 2023 by acquiring a suite of preclinical assets from Cleave Therapeutics.

Capital Expenditures

• Eikon Therapeutics plans to allocate approximately 80% of its IPO proceeds to its clinical-stage programs and 20% to preclinical activities, technology platform development, and working capital.
• Roughly $100 million of the IPO proceeds are earmarked for the clinical development of EIK1001 for advanced melanoma and non-small cell lung cancer.
• Additional allocations from IPO proceeds include $60 million for EIK1003, $40 million for EIK1004, and $20 million for EIK1005 to advance their Phase 1/2 developments.